iBio (IBIO) Non Operating Income (2010 - 2026)
iBio (IBIO) posted quarterly Non Operating Income of $635000.0 for Q1 2026, up 3427.78% year-over-year from $18000.0 in Q1 2025, and up 40.49% quarter-over-quarter from $452000.0 in Q4 2025.
iBio (IBIO) Non Operating Income (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Non Operating Income for 17 consecutive years, with $635000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 3427.78% year-over-year to $635000.0; the TTM figure through Mar 2026 stood at $1.4 million (up 283.29% YoY), while the FY2025 annual figure was $225000.0, down 81.11% from the prior year.
- Non Operating Income climbed to $635000.0 in Q1 2026 per IBIO's latest filing, from $452000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $991000.0 in Q1 2024 and bottomed at -$110000.0 in Q1 2023.
- Historically, Non Operating Income has averaged $169058.8 across 5 years, with a median of $55000.0 in 2024.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 361.9% — and 2026, when it soared 3427.78%.
- iBio's Non Operating Income stood at $10000.0 in 2022, then slipped by 20.0% to $8000.0 in 2023, then soared by 587.5% to $55000.0 in 2024, then surged by 721.82% to $452000.0 in 2025, then soared by 40.49% to $635000.0 in 2026.
- Business Quant data shows IBIO's Non Operating Income at $635000.0 in Q1 2026, $452000.0 in Q4 2025, and $231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | 635,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 635,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 163,000.00 |
| Mar 31, 2024 | 991,000.00 |
| Dec 31, 2023 | 8,000.00 |
| Sep 30, 2023 | 29,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | -110,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 66,000.00 |
| Mar 31, 2022 | 42,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 9.55 Mn |